HIRONC

HIRONIC, a global medical aesthetic device company marking its 20th anniversary in 2026, announced today that its MIGLOU™ device has received medical device approval from Korea's Ministry of Food and Drug Safety (MFDS). The approval adds MIGLOU™ to HIRONIC's growing portfolio of MFDS-certified technologies, reinforcing the company's continued investment in clinically validated, next-generation aesthetic solutions for medical professionals worldwide.  

A New Approach to Skin Tightening and Contouring

MIGLOU™ is built on HIRONIC's proprietary 2.45GHz Focused Intensive Microwave (FIM) technology, engineered to deliver targeted energy for skin tightening and contouring treatments. The platform reflects HIRONIC's ongoing commitment to developing differentiated technologies that address evolving needs in the medical aesthetics field. The approval marks another step in HIRONIC's 20th anniversary year, reflecting the company's continued focus on research-driven development and a regulation-first approach to bringing new technologies to the global aesthetic market.

Strengthening HIRONIC's Global Technology Portfolio

The MFDS approval positions MIGLOU™ alongside HIRONIC's established device lines — including New Doublo™, SYNERJET PRO™​, and PICOHI™  — as part of a comprehensive technology platform serving medical aesthetic partners in more than 60 countries. With MFDS, FDA, and CE certifications across its portfolio, HIRONIC continues to expand its footprint through a rigorous, regulation-first approach to product development.

About HIRONIC

Founded in 2006, HIRONIC is a KOSDAQ-listed medical aesthetic device company celebrating its 20th anniversary in 2026. HIRONIC develops and manufactures energy-based aesthetic devices distributed across more than 60 countries, with a portfolio spanning HIFU, RF, laser, and needle-free delivery technologies.